Müge received her Bachelor’s degree from the Department of Molecular Biology and Genetics at İhsan Doğramacı Bilkent University (Turkey) in 2019. She started her Master’s degree under the supervision of Asst. Prof. Bahar Değirmenci at İhsan Doğramacı Bilkent University. During her Master’s thesis, Müge mainly focused on the characterization of fibrogenic cells and the identification of original structures in the fibrotic liver. In June 2022 she joined Florian Greten’s lab as a PhD candidate. Currently, she is investigating cancer-associated fibroblasts and their cellular interactions with other components of the tumor microenvironment of colorectal cancer.
Dr. Fatih Ceteci
Dr. Fatih Ceteci studied biology and obtained his MSc degree in molecular biology from Uludag University (Turkey). In 2002, he started his PhD in Ulf Rapp's group at the Institute of MSZ in Wuerzburg. During his PhD, he focused on the role of MAPK signaling in murine lung cancer. In 2008, he obtained his PhD degree and continued to work as postdoctoral research scientist in the same laboratory at the Max-Planck-Institute in Martinsried. In 2012, he moved to Owen Sansom's lab as a senior postdoctoral fellow to perform research on colorectal cancer at the Beatson Institute for Cancer Research in Glasgow (UK). In December 2015, he joined the Greten lab as a staff scientist to continue working on human colorectal cancer.
Jennifer studied Biology at the Technical University of Darmstadt with the focus on biomedicine and genome biology. In 2021, she joined the start-up company WM-Therapeutics as an intern to screen potential small molecule inhibitors to target cancer cell metabolism. Jennifer completed her Master of Science in 2022 at the Paul-Ehrlich-Institute in the group of Dr. Stefan Schülke, where she worked on the contribution of immune cell metabolism to the effector function of dendritic cells activated by commercial vaccines. In May 2022 she joined Florian Greten’s lab as a PhD student, focusing on signal-transduction mechanisms affecting therapy resistance in colorectal cancer.
Dr. Claire Conche
Dr. Claire Conche studied biology at the University Paul Sabatier in Toulouse (France). For her PhD, Claire investigated the regulation of T cell activation threshold in the laboratory of Drs. Alain Trautmann & Georges Bismuth at the Cochin Institute in Paris (France). She graduated in 2009 and then joined the laboratory of Dr. Karsten Sauer at The Scripps Research Institute in Jolla (USA). There she focused on in vivo studies on T cells (development and peripheral functions), hematopoietic stem cells and blood cancers. She joined the Greten’s lab in March 2017 where she studies interactions between the immune and intestinal compartments.
Dr. Yasamin Dabiri
Dr. Yasamin Dabiri trained as a pharmacist in Tehran (Iran). In 2015, she came to Heidelberg University as a guest student, shortly after which she started her PhD at the Institute of Pharmacy and Molecular Biotechnology (IPMB) at Heidelberg University. During her PhD, she focused on developing new chemical approaches for modulation of key signaling pathways in tumorigenesis and stemness. She joined Prof. Dr. Florian Greten's lab in August 2020 where she is studying mechanisms of colorectal cancer cellular plasticity and metastasis.
Christin Danneil is responsible for the management of the mouse colony.
Dr. Dominic Denk
Dr. Dominic Denk studied medicine at Goethe University in Frankfurt, obtaining his medical degree in 2019. For his thesis, he worked in the lab of Prof. Dr. Dr. Piiper at the Department of Internal Medicine I at University Hospital Frankfurt, studying the role of tumor-penetrating peptides in improving serum marker based diagnosis in translational models of hepatocellular carcinoma. He continues working at the Department of Internal Medicine I as a physician. As a clinician scientist, Dominic joined the Greten lab in 2021, focusing on immune-mediated antitumor responses in colorectal cancer. .
Bert de Valk
Bert has obtained his master’s degree in Bio-pharmaceutical sciences in September 2020. During his studies he was involved in the synthesis and testing of an affinity based probe for the CCR2 receptor at the Leiden academic centre for drug research. Next to this he was active at Merck in Darmstadt where he was responsible for the crystallisation of proteins and automatization of this process by training and implementing an image classifier. After working in quality at Johnson and Johnson he joined Florian Greten’s lab in May 2022 as a PhD student to investigate the roles of fibroblasts in rectal cancer and their implication on current cancer therapies.
Esther Engel studied Biology at the Leibniz University Hannover and received her diploma in 2007. After that she worked for several institutes, especially focusing on in vivo models. Since September 2019 she joined the Greten lab funded by the LOEWE Center Frankfurt Cancer Institute examining therapy response of rectal cancer patients.
Kilian studied medicine at the University of Heidelberg and received his degree in 2019. During his studies, he joined the translational surgical oncology research group of Prof. Martin Schneider at the Department of General, Visceral and Transplantation Surgery at Heidelberg University Hospital. There, he studied the role of HIF-Prolyl hydroxylases in the development of colitis-associated carcinoma. Kilian joined the Greten lab in September 2019 as a PhD candidate and is currently investigating into the role of cancer-associated fibroblasts as well as deubiquitinating enzymes in colorectal cancer.
Hana Kunkel joined the Greten lab in 2016 and is responsible for lab management.
Kathleen worked as a Research Assistant at Oregon Health & Science University in Portland Oregon (USA) for 12 years before joining the group already in Munich in 2012. She is responsible for pre-clinical studies.
Dr. Marina Pešić
Dr. Marina Pešić graduated at University of Belgrade (Serbia), Faculty of Biology in 2007. During her diploma thesis she worked in Prof. Jelena Milasin’s laboratory of Cytogenetics and Molecular Genetics, Institute of Biology and Human Genetics, School of Dentistry, University of Belgrade (Serbia). In 2008, she started PhD in Prof. Lars Zender’s group at the Helmholtz Centre for Infection Research in Braunschweig before moving with the group to University Hospital Tübingen. During her PhD work she was applying RNAi based functional genetic and genomic approaches to study liver cancer and liver regeneration. She was involved in the development of transposon based stable shRNA technology that can be used to conduct pooled shRNA screens directly in vivo. She joined the Greten lab as a Postdoc in 2014. She is currently working on the functional identification of new modulators of metastasis in colon cancer.
Dr. Birgit Ritter
Dr. Birgit Ritter studied biology at the Friedrich-Schiller University in Jena. In 2010 she started her PhD in the lab of Falk Nimmerjahn at the University of Erlangen, investigating the role of effector cells in antibody-dependent melanoma therapy. After continuing as a postdoc to work on antibody therapy in colitis, she joined the Greten lab in 2016 as a staff scientist. Here, she is entrusted with the human CRC biobank, scientific coordination and writing of regulatory applications. Since 2018 she has also been head of our histology department.
Eva received her training as a medical technical assistant in 1999 in Würzburg and joined the Georg-Speyer-Haus in 2005.